SOLV (SolvProtocol) fluctuated 40.3% in 24 hours: trading volume surged over 200%, driving sharp price volatility
Bitget Pulse2026/04/18 18:39Brief Overview of Volatility
In the past 24 hours, SOLV price rebounded from a low of $0.004050 to a high of $0.005680 and is currently quoted at $0.004070, with a fluctuation amplitude of 40.3%. The 24-hour trading volume surged to approximately $40-51 million (CoinGecko data shows $40.3 million, CMC $51.38 million), more than a 200% increase compared to the previous day, while net capital outflow remained limited (around -$6,000).
Brief Analysis of Abnormal Movement Reasons
• Extraordinary Trading Volume Expansion: 24-hour trading volume reached $40-51 million, increasing over 200%, directly driving the rapid price surge from the low and subsequent oscillation, making it the primary driver for this abnormal movement.
• Increased On-chain Activity: 24-hour fee revenue increased by 31.9%, TVL remained at the high level of $847 million, DEX net inflow slightly increased by $103, indicating enhanced capital participation.
• No official announcements or major news events in the past 24 hours, and no public whale large transaction alerts observed.
Market Views and Outlook
Mainstream sentiment in the X community is bullish. Multiple traders have highlighted whale bidding, insider signals, and support level rebounds, forecasting a short-term target above $0.005 (such as "$SOLV is next one to pump, Breaking out" and "Whales are bidding"). Analysts are focusing on the sustainability of trading volume, suggesting that if the $0.0043 support holds, the rebound may continue; otherwise, the downside risk increases.
Note: This analysis is automatically generated by AI based on public data and on-chain monitoring, for informational reference only.Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion
The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.
Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight
Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.
Eli Lilly (LLY.US) "lowers its stance" and joins forces with former rival Hims (HIMS.US) to compete for the self-pay weight loss drug market
Eli Lilly is collaborating with Hims & Hers Health, leveraging the telehealth company’s large customer base to expand access to its blockbuster weight loss drugs and boost sales of medications, including its new oral weight loss drug Foundayo.
Crypto prices
More
